Coyne Scientific’s unique platform – delivering genetic diversity, in vitro – opens the door to game-changingadvances in the safety and cost of developing new drugsRead more...

Early – and accurate – cardiac risk assessment, based on pre-clinical testing of large numbers of identically-prepared cell lines reflecting representative samples of target populations, not just one random cell lineRead more...

EARLY RISK ASSESSMENT

Early detection – and early termination or modification – of candidate drugs that would later fail in clinical trialsRead more...

EARLY DETECTION

ENHANCED SAFETY

Enhanced safety for target populations that are not adequately protected by clinical trialsRead more...

Coyne Scientific: Genetic Diversity, In Vitro

Because...

•

Genetic differences among humans drive differences in their responses to pharmaceutical drugs

...and...

•

Cardiomyocytes derived from the iPSCs of specific humans recapitulate the responses of their hearts when exposed to drugs in clinic

…it’s now possible to change the paradigm in pharmaceutical drug development...

Early and accurate cardiac risk assessment, based on pre-clinical testing of large numbers of identically-prepared cell lines reflecting representative samples of target populations, not just one random cell line

•

Early detection – and early termination or modification – of candidate drugs that would later fail in clinical trials

•

Enhanced safety for target populations that are not adequately protected by clinical trials

•

Deeper understanding of pharmacodynamic drug-drug interaction effects

•

Practical applications in the arena of personalized toxicology

Intrigued? Read on...

Our Company

Coyne Scientific (“CoyneSci”) is an emerging biotech services company seeking to make a major difference in worldwide health by…